Key Takeaways:
Biotech's 2026 rally hit a wall Friday as three of the sector's best-performing names gave back double-digit percentages in a broad profit-taking flush.
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run. Moderna Inc. stock dropped 11% to $68.50, ImmunityBio Inc. fell 8% to $8.16, and Sarepta Therapeutics Inc. slid 8% to $18.84 — all on no company-specific negative news.
"There's no fundamental catalyst here," said Sam Goldstein, a biotech analyst. "This is pure profit-taking after a parabolic move. Moderna was up 160% year to date through Thursday, and ImmunityBio had gained 348%. When stocks run that hard, they don't need a reason to correct."
The moves landed on top of extraordinary year-to-date gains. Moderna shares had climbed 160% through Thursday's close, while ImmunityBio had surged 348%. The SPDR S&P Biotech ETF, which holds all three names among its equal-weighted constituents, fell 4% at midday, framing the selloff as a sector-wide unwind rather than a single-name blowup. Recent news flow on all three was actually bullish: Sarepta was just upgraded by Wolfe Research to Outperform with a $27 target, and Moderna's Q1 2026 revenue of $389 million beat consensus by 65%.
Profit-taking after a historic run
The rotation angle sharpens when you look outside biotech. Eli Lilly & Co. shares fell just 3% at midday, while Johnson & Johnson dropped 1%. That gap tells the story: money is rotating out of high-beta, pre-profit biotech names and holding steady in defensive large-cap pharma, where Eli Lilly is still up 10% year to date and Johnson & Johnson has gained 24%.
Moderna's near-term catalyst is the Aug. 5 PDUFA date for mRNA-1010, its seasonal flu vaccine candidate. The company's pipeline includes Spikevax, mRESVIA, mNEXSPIKE, and mCOMBRIAX, and management has guided for year-end cash of $4.5 billion to $5 billion. Still, the stock remains down 71% over five years, and the company posted a $1.34 billion GAAP net loss in Q1, underscoring the cash burn that makes these names vulnerable during sector flushes.
ImmunityBio has ridden Russell 1000 inclusion hopes and Anktiva optimism to its triple-digit gain, with Q1 2026 revenue of $44.21 million up 168% year over year. Sarepta's Wolfe Research upgrade to Outperform with a $27 target implied 34% upside from Thursday's close — before today's selloff erased a chunk of that gap.
What to watch next
The immediate tell is whether XBI stabilizes into the close or accelerates lower, which would signal the rotation has more room to run. Even after today's drop, the ETF is still up 78% over the past 12 months. Moderna's Aug. 5 PDUFA decision is the next hard-dated catalyst on the calendar.
For investors holding these names, today's action is a reminder of how quickly biotech beta cuts both ways. Moderna shares trade with a beta of 2.31, meaning outsized swings in both directions. The bull case — a deep pipeline, a potential flu vaccine approval, and $4.5 billion-plus in year-end cash — remains intact. But the bear case — chronic unprofitability, heavy cash burn, and a stock still down 71% over five years — means position sizing matters. The selloff looks like an unwind after a historic rally rather than a fundamental rerating, but in biotech, the difference often doesn't matter until the selling stops.
This article is for informational purposes only and does not constitute investment advice.
